Scientists recommend wider use of clot-busting stroke drug

09/25/2008 | Wall Street Journal, The

A stroke drug from Genentech called tissue plasminogen activator, marketed as Activase in the U.S., can be administered 4 1/2 hours after the onset of stroke symptoms -- past the three-hour limit recommended by the FDA -- a study concluded. Researchers found that 52% of patients who received TPA more than three hours after suffering a stroke survived with little impairment based on the Rankin scale while the rate for those who got placebo was 45%. The study was conducted in Europe by Boehringer Ingelheim, Genentech's business partner.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA